| Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations |
Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene |
globenewswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights |
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years |
globenewswire.com |
2025-05-12 20:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting |
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells |
globenewswire.com |
2025-04-29 13:05:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 |
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an oral presentation at the World Vaccine Congress Washington 2025, held April 21-24, 2025, in Washington, D.C. |
globenewswire.com |
2025-04-24 11:55:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 |
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C. |
globenewswire.com |
2025-04-16 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies |
Agreement includes the use of Tonix's TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana's genetically engineered pig organs in xenotransplantation |
globenewswire.com |
2025-04-09 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting |
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia |
globenewswire.com |
2025-04-07 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference |
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D. |
globenewswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition |
CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a fully-integrated digital platform designed to help patients better understand and manage their migraine condition. |
globenewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year |
CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accessnewswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting |
CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D. |
globenewswire.com |
2025-03-27 09:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years |
PDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Committee Meeting of TNX-102 SL for the treatment of patients with Fibromyalgia. TNX-102 SL met primary endpoints in two Phase 3 studies, showing significant pain reduction, positioning it as the first new Fibromyalgia drug in 15 years. |
seekingalpha.com |
2025-03-26 04:30:07 |
Czytaj oryginał (ang.) |
| Pharma Frenzy: Volatility Ignites Biotech Sector |
The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO. The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions. |
marketbeat.com |
2025-03-25 11:10:16 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia |
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025 CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Company's New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia. |
globenewswire.com |
2025-03-24 10:00:00 |
Czytaj oryginał (ang.) |
| As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread |
Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading - infects mostly gay men CHATHAM, NJ / ACCESS Newswire / March 20, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accessnewswire.com |
2025-03-20 09:00:00 |
Czytaj oryginał (ang.) |
| Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. |
benzinga.com |
2025-03-19 10:15:46 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonstrated single-dose immune protection against a monkeypox challenge in non-human primates Received first payments from U.S. Department of Defense (DoD) contract for up to $34 million over five years to develop a broad-spectrum antiviral drug program CHATHAM, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent operational highlights. |
globenewswire.com |
2025-03-18 18:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 |
CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D. |
globenewswire.com |
2025-03-13 09:00:00 |
Czytaj oryginał (ang.) |
| Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target |
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accessnewswire.com |
2025-03-12 09:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th |
CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, at 3:30 p.m. ET. |
globenewswire.com |
2025-03-11 09:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash |
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 |
globenewswire.com |
2025-02-07 10:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases |
Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection |
globenewswire.com |
2025-02-06 10:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference |
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City. |
globenewswire.com |
2025-02-05 09:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer |
Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with U.S. FDA PDUFA goal date of August 15, 2025 CHATHAM, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the promotion of Siobhan Fogarty to Chief Technical Officer (CTO), effective immediately. |
globenewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split |
CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-100 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on February 5, 2025. |
globenewswire.com |
2025-02-03 10:05:00 |
Czytaj oryginał (ang.) |
| Is Tonix Pharmaceuticals the Next Biotech Breakout? |
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals NASDAQ: TNXP is gaining significant attention from investors and market participants. The company develops therapies for conditions with high unmet needs, with a focus on pain management, CNS disorders, and public health vaccines. |
marketbeat.com |
2025-01-30 14:01:58 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia |
Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 |
globenewswire.com |
2024-12-23 10:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia |
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter |
globenewswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights |
Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies |
globenewswire.com |
2024-12-16 13:40:00 |
Czytaj oryginał (ang.) |
| Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers |
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accesswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference |
CHATHAM, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present and conduct investor meetings at NobleCon20, Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, being held December 3-4 in Boca Raton, Fla. |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed |
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. |
globenewswire.com |
2024-11-21 06:27:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual |
CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Winter 2024 Investor Summit Virtual on Thursday, November 21, 2024, at 10:00 a.m. ET. |
globenewswire.com |
2024-11-18 18:05:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments |
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accesswire.com |
2024-11-14 09:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting |
CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver a poster presentation at the ACR Convergence 2024 Annual Meeting, which will be held in Washington, D.C., November 14-19, 2024. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the ACR website here. |
globenewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals |
The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years |
globenewswire.com |
2024-11-13 11:05:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 |
New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix's attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals |
globenewswire.com |
2024-11-01 09:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Present at BIO-Europe® 2024 |
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET. |
globenewswire.com |
2024-10-29 10:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference |
CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City. |
globenewswire.com |
2024-10-25 12:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) |
NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant results on the primary endpoint of reducing widespread pain; generally well tolerated |
globenewswire.com |
2024-10-16 12:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals |
AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures |
globenewswire.com |
2024-10-08 12:30:00 |
Czytaj oryginał (ang.) |
| The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions |
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accesswire.com |
2024-10-01 11:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines |
New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No. |
globenewswire.com |
2024-09-27 11:00:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines |
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No. |
globenewswire.com |
2024-09-19 11:00:00 |
Czytaj oryginał (ang.) |
| New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution |
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. |
accesswire.com |
2024-09-18 11:30:00 |
Czytaj oryginał (ang.) |
| Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency |
The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox vaccines at its Mpox Research and Innovation Scientific Conference held August 29-30 |
globenewswire.com |
2024-09-16 11:00:00 |
Czytaj oryginał (ang.) |